Novo Nordisk to focus on patient outreach, prescribing doctors and subsidies to reach obesity goals
Today, around 125,000 severely obese patients in the US are being treated with one of Novo Nordisk’s obesity drugs. Still, the real demand is yet unclear to the Danish pharmaceutical firm.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
Obese patients can feel confused and stigmatized, and reaching out to men in particular can be difficult. On top of this, Danish pharmaceutical firm Novo Nordisk has recently been hit by big production issues.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk more than doubles 2025 obesity sales goal
For subscribers
.jpg&w=384&q=75)
